PRLog (Press Release) –
Mar 25, 2008 – Now in its fourth year, the summit will once again provide a landscape and in-depth industry analysis streaming through different therapeutic and target areas and examining the current advancements and where we’re headed in the coming years.
The M3D summit will include 6 full conference tracks, 3 short symposia, and 6 mini stand-alone sessions. The individual tracks will focus on biological therapeutics, translational medicine, drug design & lead discovery, emerging targets & therapeutics, pharmacokinetics & pharmacodynamics, and partnering, licensing & outsourcing. The 3 short symposia taking place the first morning of the summit will feature presentations on stem cells as tools for drug discovery, imaging technologies, and regulatory updates in the industry.
Leading presenters from all over the world will come to San Diego to discuss the outlook of the biopharmaceutical market place. Presenting organizations include, Pfizer, Merck, Novartis, Eli Lilly, GSK, Aventis, Genentech, Amgen, Biogen Idec, NIH, FDA & many more.
For more information on speaking, presenting a poster, or sponsoring, please visit www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
